Physician profile
Ann M Dechellis
NPI 1881206993
$5,120.71
in general payments reported to CMS, 2019-2025
30 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $262 · 2022: $463 · 2023: $1,439 · 2024: $1,673 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,204 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,203.62 |
| Education | $191.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,162.22 | 2021-2025 | |
| Janssen Biotech, INC. | $1,008.66 | 2021-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $449.28 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $368.50 | 2021-2025 | |
| Genzyme Corporation | $248.51 | 2021-2025 | |
| Lilly USA, LLC | $196.70 | 2023-2025 | Taltz, Ebglyss |
| Ucb, INC. | $170.40 | 2023-2025 | Bimzelx |
| Merz North America, INC. | $163.53 | 2025 | |
| Incyte Corporation | $156.94 | 2022-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $151.26 | 2023-2025 | Blu-U, Odomzo |
| Dermavant Sciences, INC. | $122.55 | 2023 | Vtama |
| Amgen INC. | $105.83 | 2024-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $100.21 | 2022-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Janssen Scientific Affairs, LLC | $89.51 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $87.09 | 2024-2025 | Aklief, Nemluvio |
| Organon LLC | $56.21 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.63 | 2023 | Spevigo |
| Organogenesis INC. | $44.56 | 2024-2025 | Cygnus Dual |
| Arcutis Biotherapeutics, INC. | $40.15 | 2023 | |
| Journey Medical Corporation | $34.75 | 2025 | |
| Pfizer INC. | $30.41 | 2023-2025 | |
| Convatec INC. | $28.63 | 2023 | |
| Leo Pharma INC. | $27.71 | 2022 | |
| Kerecis Limited | $25.35 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Revance Therapeutics, INC. | $21.00 | 2025 | Daxxify |
| Mayne Pharma Commercial LLC | $20.20 | 2025 | |
| Kyowa Kirin, INC. | $19.61 | 2024 | Poteligeo |
| Botanix Sb INC | $19.13 | 2025 | Sofdra |
| Mimedx Group, INC. | $18.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Dechellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.